Skip to content

Topical Rho kinase inhibitor for treatment of Fuchs endothelial corneal dystrophy

A prospective study of topical Rho kinase inhibitor (Ripasudil) for treatment of Fuchs endothelial corneal dystrophy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250107001
Enrollment
20
Registered
2025-01-07
Start date
2025-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fuchs endothelial corneal dystrophy Topical Rho kinase inhibitor Ripasudil Fuchs endothelial corneal dystrophy

Interventions

0.4% Ripasudil eye drop to randomized eye, 4 times per day for 6 months 5% sodium chloride eye drop to randomized eye, 4 times per day for 6 months 0.18% sodium hyaluronate) eye drop to randomized eye
Experimental Drug,No Intervention No treatment
Ripasudil,control

Sponsors

Faculty of Medicine Siriraj Hospital, Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with corneal dystrophy stage 1 or stage 2 2. Older than 18 years old.

Exclusion criteria

Exclusion criteria: 1. Patients with eye inflammation or infectious eye inflammation or have had a viral infection of the cornea. 2. Patients who are pregnant or plan to become pregnant within 1 year or breastfeeding. 3. Patients who have had a corneal transplant before.

Design outcomes

Primary

MeasureTime frame
Central corneal thickness At first visit, 1 month, 3 months and 6 months after start drug Compare central corneal thickness by Anterior Segment Optical Coherence Tomography

Secondary

MeasureTime frame
Number of endothelial cell and endothelial cell morphology At first visit, 1 month, 3 months and 6 months after start drug Compare Number of endothelial cell and endothelial cell morphology by ConfoScan4 confocal microscope

Countries

Thailand

Contacts

Public ContactWipawee Booranapong

Faculty of Medicine Siriraj Hospital, Mahidol University

si93wbr@gmail.com0944245922

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026